Navigation Links
Stem Cell Finding Could Help Reduce Transplant Rejection

A new study involving a type of stem cells from the lungs of transplant patients demonstrates for the first time that these progenitor cells //reside in adult organs and are not derived from bone marrow, which leads to the possibility that the cells may be able to help with the rejection of donated organs and with various kinds of lung disease.

The study by University of Michigan Health System researchers is significant because of the large number of lung transplant patients who experience chronic rejection of donated lungs, with rejection rates of about 60 percent during the first five years after transplantation.

The researchers studied mesenchymal stem cells (MSCs), a type of progenitor cell that most commonly originates in the bone marrow. In this study, lead author Vibha N. Lama, M.D., M.S., and her research team found that the MSCs in lung transplant patients are not derived from bone marrow, but rather that they reside – sometimes for many years – in the lungs. The researchers also found that these cells have the capacity to differentiate into multiple connective tissue cell types.

One of the most telling findings was that, in cases where the transplant donor and recipient were not of the same sex, nearly all the MSCs (about 97 percent) originated in the donor, indicating that they were present in the tissue since the time of transplantation. “We were able to isolate the cells derived from the donor as far as 11,5 years after transplantation,” says Lama, assistant professor in the Division of Pulmonary and Critical Care Medicine at the U-M Medical School. “We discovered the existence of a population of MSCs that reside and self-renew in the tissues of the adult lung – something that might hold true for other organ systems as well.

“Potentially the most important outcome of our finding is that it could lead to an understanding about therapeutic options using MSCs that reside in adult organs,” Lama continues. “These lung-derived cells are different from MSCs derived from bone marrow in the expression of various genes, which makes us believe that they are specific to the organ they are isolated from.”

The study appears online March 8 in advance of publication in the April print issue of the Journal of Clinical Investigation.

MSCs are widely seen as a potential source of therapies for numerous diseases and conditions, such as heart disease, cystic fibrosis, graft-versus-host disease, muscular dystrophy, and as a possible source for improved recovery of cancer patients undergoing chemotherapy.

Lama’s laboratory currently is working on another study involving the lung-derived MSCs that shows potential importance of these cells in lung transplantation. That study is not yet complete, but so far it indicates a very strong ability of these MSCs to suppress the immune cells that are involved in organ rejection. In addition to helping prevent organ rejection, other possible uses for the lung-derived MSCs could be therapies related to heart attack and pulmonary fibrosis, Lama says.

MSCs are termed progenitor cells; that is, they can differentiate into only limited number of cell types such as bone, cartilage and fat cells. However, previous laboratory studies have demonstrated the beneficial effect of these cells in various diseases, such as models of heart attacks and pulmonary fibrosis.

The current study of MSCs included 172 bronchoalveolar lavage fluid samples collected and analyzed from 76 lung transplant recipients at the U-M Health System. The ability to isolate these cells with relative ease from lavage fluid is a very significant finding as it provides a potential source to isolate MSCs, says Victor J. Thannickal, M.D., associate professor of Internal Medicine in the Division of Pulmonary and Critical Care Medicine and senior author on this study. “The specific roles of these cells in chronic lung diseases are yet to be fully defined, but will be an active area of research in years to come.”

Source-Newwise
SRM
'"/>




Related medicine news :

1. Finding relief from Excruciating Headaches a challenge
2. Latest Findings On The Deadly Disease - SARS
3. New Findings Could Reduce The Extent Of Spinal Cord Injuries
4. Surprising Cystic Fibrosis Finding That Could Be A Helpful Treatment Option
5. New Findings for Repeated Miscarriages
6. Finding The Key To Weight Loss!
7. Internet Helps Patients In Finding Info About Their Childrens Health Conditions
8. How Healthy Are Herbal Products? US Findings.
9. Dispute in Findings about Radiation exposure
10. New Findings on Autism Research
11. Engineering Nutrient-Rich Plants Made For Feasible By New Findings
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... ... 2017 , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the ... ClearLungs Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength ... , Removal of the homeopathic element , Adding their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to May ... Medicine will host industry leaders for the annual spring Convention & Expo, called ... industry adapt to the issues currently affecting urgent care and on-demand healthcare. , ...
Breaking Medicine News(10 mins):
(Date:4/25/2017)... 2017 Endo International plc (NASDAQ: ENDP ) ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 6086379. Please dial in 10 minutes prior to ... replay of the call will be available from May 9, 2017 ...
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
Breaking Medicine Technology: